FEB 21, 2018 6:00 AM PST

Using HDAC Inhibitors to Improve Cancer Immunotherapy

Presented at: Drug Discovery 2018
Speaker
  • Assistant Professor of Biochemistry and Molecular Medicine, GW School of Medicine and Health Sciences
    Biography
      Dr. Villagra's areas of expertise are epigenetics and tumor immunology. During his early scientific career, he explored different aspects of epigenetic regulation including DNA methylation, ATP-dependent chromatin remodeling complexes, histone acetyltranferases and histone deacetylases. His study models have been diverse and have included myogenic and osteoblastic differentiation, gene regulation of immune-related pathways and tumor immunology. Over the last several years, his group has focused on the study of the role of different epigenetic modifiers in the modulation of anti-tumor immune responses, assigning a special emphasis to the identification of potential therapeutic agents to improve immunotherapy. Dr. Villagra's group experimental approaches have important translational components, which allow them the possibility to extend their research into the clinical area. These particular characteristics help provide continuous scientific feedback and keep goals focused on relevant biomedical aspects of research.

    Abstract

    We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one of the natural ligands for the PD-1 receptor present on T-cells, consistently reported to suppress T-cell activation, proliferation, and induce T-cell exhaustion, anergy and apoptosis. As a result, increased PD-L1 expression by cancer cells remains a fundamental escape mechanism from host immunity within the tumor microenvironment, and the understanding the molecular mechanisms modulating PD-L1 and other immunosuppressive mediators could lead to improved treatments for cancer patients. Several publications have linked the over-expression of PD-L1 in tumors and tumor microenvironment with a poor prognosis in several malignancies, including melanoma, ovarian, gastric and breast cancer, among many others. However, more detailed mechanistic information regarding the molecular events involved in the regulation of PD-L1 is still missing. Moreover, limited information is available about the participation of preclinical and clinical anti-cancer agents in the regulation of PD-L1 and other immunomodulatory pathways. As a result, this gap in knowledge is preventing the design of new immunotherapeutic combination therapies. Given the fact that HDAC6 is a potential regulator of immunosuppressive mediators, it opens up a new avenue for immunotherapy. By using selective HDAC6inh as adjuvants to ongoing immune blockade based treatments, we are aiming to further augment anti-tumor immune responses.   


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    FEB 21, 2018 6:00 AM PST

    Using HDAC Inhibitors to Improve Cancer Immunotherapy

    Presented at: Drug Discovery 2018

    Specialty

    Immuno-Oncology

    Health

    Research And Development

    Regulatory Affairs

    Marketing

    Earth Science

    University

    Fda

    Pharmaceutical

    Research

    Prescription Drug

    Cancer

    Geography

    North America50%

    Asia50%

    Registration Source

    Website Visitors100%

    Job Title

    Student50%

    Medical Laboratory Technician50%

    Organization

    Academic Institution50%

    Manufacturer - Other50%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more